How access to Wegovy works in the UK — and what most people get wrong

The myth that gets most people stuck: Wegovy is easy to get on the NHS right now

The most common misconception is that Wegovy became straightforwardly available when NICE approved it. NICE's recommendation (TA875, published March 2023) is real, but it comes with conditions that rule out the majority of people who enquire. Under that guidance, NHS Wegovy is restricted to adults within a specialist weight management service (typically tier 3 or above) and the maximum treatment duration is two years. BMI thresholds start at 35, reduced by 2.5 kg/m² for people from certain ethnic backgrounds. Referrals to those services can take months; in many parts of England the waiting lists run longer still.

That gap between approval and access is precisely why private prescribing exists. A regulated online pharmacy can issue a private prescription following a full clinical assessment, with no referral and no waiting list, provided you meet the licensed eligibility criteria. The medicine is the same; the route is different. The team behind nume set up with that gap in mind.

What the licensed eligibility criteria for Wegovy actually say

The UK licence for Wegovy covers adults with a BMI of 30 or above, or 27–29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, or obstructive sleep apnoea. Those figures are the floor, not the ceiling: a prescriber looks at your full clinical picture, not a BMI number in isolation. Conditions that might make Wegovy unsuitable (a personal or family history of certain thyroid cancers, a history of pancreatitis, pregnancy or breastfeeding) are assessed at the consultation stage.

If you are comparing Wegovy and tirzepatide (Mounjaro), the eligibility thresholds are similar on paper, though the clinical profiles differ. The semaglutide information page covers the pharmacology in more detail. BMI alone never decides the outcome; it is the starting point for a conversation with a prescriber, not the answer.

Worth knowing: Wegovy is a Black Triangle (▼) medicine, meaning the MHRA has it under enhanced monitoring while post-market safety data continues to accumulate. That does not reflect doubt about its effectiveness, as you can see from the data on how often Wegovy produces clinically meaningful results for patients who complete the titration schedule, and from the broader picture of what wegovy weight loss success looks like across real-world patients. You can also read NICE's full appraisal of semaglutide (TA875) for the evidence base behind the recommendation.

How the dose schedule works in practice, and why starting low matters

A detail that surprises many people: Wegovy does not start at its treatment dose. The schedule opens at 0.25mg weekly for the first four weeks, steps to 0.5mg, then 1.0mg, then 1.7mg, before reaching the standard 2.4mg maintenance dose at around week sixteen. Each step is managed by your prescriber; you do not self-escalate. The gradual titration exists because the most common side effects (nausea, loose stools, indigestion) are most pronounced when the dose changes, and a slower ramp dramatically reduces how disruptive they are for most people.

Storage follows the same pattern as most injectable medicines: the pen lives in the fridge door between uses, at 2–8°C, and should be brought briefly to room temperature before injection. The exact window for room-temperature storage is in the Patient Information Leaflet; follow that, not summaries. Injections go into the abdomen, thigh, or upper arm, rotating sites each week.

For those already established on Wegovy who want to understand what success looks like over time, reading an account of how treatment progressed for a real patient on Wegovy can set realistic expectations alongside the trial data. The STEP 1 trial, published in the New England Journal of Medicine, recorded an average body-weight reduction of around 15% over 68 weeks at 2.4mg alongside lifestyle changes.

Getting access through a private prescription: the legal route explained

Private prescribing for Wegovy is legal in the UK when carried out by a qualified prescriber following a proper clinical assessment. The requirement is not a formality, it is the mechanism that makes the supply lawful and, practically, the thing that keeps you safe. A consultation covers your medical history, current medications, weight history and any contraindications. For tirzepatide users considering a switch, or for anyone transferring from another provider, current treatment evidence is reviewed before any prescription is issued.

At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician, not an automated decision engine. Orders placed before midday on a working day are dispatched the same day once clinically approved, arriving by tracked DPD delivery the next working day in plain packaging. There are no subscriptions and no automatic renewals; each repeat order goes through a fresh clinical review. If you want to understand what getting the most out of your Wegovy treatment looks like in practice before starting, that page walks through the habits and clinical factors that tend to make the difference, and you can find further practical guidance on the wegovy tips for success page, which covers the day-to-day approaches that support the best outcomes. You can verify our pharmacy on the GPhC register at registration number 9012878.

On cost: private Wegovy is a meaningful monthly outlay. The treatment page shows current pricing, which covers the consultation, prescription, medicine and next-working-day delivery with no hidden extras. Cheapest is not the benchmark to use for a prescription medicine, legitimate supply through a verified pharmacy is. The MHRA has warned publicly about counterfeit weight-loss pens sold online; if a price looks implausibly low or a seller offers supply without a prescription, that is a serious red flag.